Nikkilä, Jenni
Kumar, Rahul
Campbell, James
Brandsma, Inger
Pemberton, Helen N
Wallberg, Fredrik
Nagy, Kinga
Scheer, Ildikó
Vertessy, Beata G
Serebrenik, Artur A
Monni, Valentina
Harris, Reuben S
Pettitt, Stephen J
Ashworth, Alan
Lord, Christopher J
Article History
Received: 16 December 2016
Revised: 18 April 2017
Accepted: 24 April 2017
First Online: 23 May 2017
Competing interests
: RSH is a co-founder, shareholder and consultant of ApoGen Biotechnologies, Inc. CJL and AA are inventors on patents describing the use of PARP inhibitors and stand to gain from their development as part of the ICR, ‘Rewards to Inventors’, scheme. All authors have read and approved the final draft of the manuscript.